ReviewContrast media & molecular imaging2019
Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models.
Review in Contrast media & molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Nanoscale-Sensitive VSFG Microscopy for Identifying Breast Tumor in FFPE Samples.Chemical & biomedical imaging · 2026Article
- Ultrasound medicine in the era of precision theranostics: Mechanisms, molecular strategies, and clinical translation.Iranian journal of basic medical sciences · 2026Review
- Dual-targeting and steric hindrance resolution in HER2 IHC: a novel approach to improve diagnostic sensitivity.BMC cancer · 2025Article
- Synergistic Effects of Cryotherapy and Radiotherapy in Glioblastoma Treatment: Evidence from a Murine Model.Cancers · 2025Article
- Multimodality Imaging Features of Papillary Renal Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Advancements in noninvasive techniques for transplant rejection: from biomarker detection to molecular imaging.Journal of translational medicine · 2025Review
- Optical imaging guidance in oncologic surgery and interventional oncology.Pharmacological research · 2025Review
- Contrast-enhanced photon-counting micro-CT of tumor xenograft models.Physics in medicine and biology · 2024Article
- Contrast-enhanced photon-counting micro-CT of tumor xenograft models.bioRxiv : the preprint server for biology · 2024Article
- Sensitive, non-immunogenicCell stress · 2023Article
- Evaluation of Apparent Diffusion Coefficient Repeatability and Reproducibility for Preclinical MRIs Using Standardized Procedures and a Diffusion-Weighted Imaging Phantom.Tomography (Ann Arbor, Mich.) · 2023Article
- Translating a radiolabeled imaging agent to the clinic.Advanced drug delivery reviews · 2022Review
- Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy.Oxidative medicine and cellular longevity · 2022Article
- In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [EJNMMI research · 2021Article
- Artificial intelligence and guidance of medicine in the bubble.Cell & bioscience · 2021Article
- Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.Contrast media & molecular imaging · 2021Article
- Functionalized nanoparticles with targeted antibody to enhance imaging of breast cancer in vivo.Journal of nanobiotechnology · 2020Article
- Article
- Shortwave Infrared-Emitting Theranostics for Breast Cancer Therapy Response Monitoring.Frontiers in molecular biosciences · 2020Article
- Magnetic Resonance Imaging for Translational Research in Oncology.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision and personalized medicine is gaining importance in modern clinical medicine, as it aims to improve diagnostic precision and to reduce consequent therapeutic failures. In this regard, prior to use in human trials, animal models can help evaluate novel imaging approaches and therapeutic strategies and can help discover new biomarkers. Breast cancer is the most common malignancy in women worldwide, accounting for 25% of cases of all cancers and is responsible for approximately 500,000 deaths per year. Thus, it is important to identify accurate biomarkers for precise stratification of affected patients and for early detection of responsiveness to the selected therapeutic protocol. This review aims to summarize the latest advancements in preclinical molecular imaging in breast cancer mouse models. Positron emission tomography (PET) imaging remains one of the most common preclinical techniques used to evaluate biomarker expression
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.